⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →

FDC Ltd (FDC)

Healthcare · Pharmaceuticals · NSE · Updated 3 September 2026
By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings
₹339.95 ↓ 26.73% (1Y)

🎯 Key Takeaways

  • FDC Ltd is in a mature phase with stable profitability and minimal debt, operating in the pharmaceuticals sector with a focus on regulated consumer healthcare products. The company has demonstrated consistent margins and strong returns on capital, but faces near-term headwinds reflected in a 26.
  • Revenue grew 14.2% QoQ to ₹668 in Q1FY27.
  • ⚠️ The company's profitability appears highly sensitive to quarterly fluctuations, with operating profit declining from ₹128 crore in Q1FY27 to ₹92 crore
Market Cap
₹5,535
P/E Ratio
18.9
P/B Ratio
2.43
ROE
12.8%
ROCE
17.3%
Debt/Equity
0.00
Div Yield
1.47%
Promoter
69.7%
✨ Ask AI About FDC 📊 Interactive Charts

📖 The Story

FDC Ltd is in a mature phase with stable profitability and minimal debt, operating in the pharmaceuticals sector with a focus on regulated consumer healthcare products. The company has demonstrated consistent margins and strong returns on capital, but faces near-term headwinds reflected in a 26.61% year-on-year decline in stock performance. Recent governance updates and regulatory clearances suggest operational continuity, but growth appears limited in the near term.

⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →

📰 What's Happening

In Q1FY27, FDC secured an interim stay from the Delhi High Court on an FSSAI mislabeling notice related to its electrolyte drink products, allowing an eight-month window to relabel without financial or operational disruption. The company also advanced the appointment of Mr. Kishore Mukund Saletore as an Independent Director via a special resolution approved through a postal ballot process, effective April 1, 2026, with e-voting conducted between April 28 and May 27, 2026. These actions reflect routine governance updates rather than strategic shifts, with compliance emphasized across shareholder communications and regulatory filings.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

MetricSep 2025Dec 2025Mar 2026Jun 2026
Revenue473465585668
Operating Profit193892128
OPM %3.9%8.1%15.7%19.1%
Net Profit2828103132
EPS₹1.75₹1.74₹6.35₹8.14

FDC has shown a clear upward trend in revenue and profitability over the past four quarters, with June 2026 revenue of ₹668 crore marking a significant increase from ₹465 crore in December 2025. Operating margins expanded from 8.1% in Q3FY26 to 19.1% in Q1FY27, and net profit rose from ₹28 crore to ₹132 crore over the same period, indicating strong operational momentum. This improvement aligns with increased scale in core product lines, though the company did not explicitly attribute growth to new launches or market expansions in its recent filings.

🔮 Management Outlook & What's Next

FDC's management has not provided forward-looking financial guidance in the reviewed filings. The most recent commentary focuses on regulatory compliance, governance updates, and court-ordered resolutions rather than growth projections or market outlook. There is no explicit discussion of revenue targets, margin expectations, or capital allocation strategy beyond routine operational continuity, suggesting a conservative or neutral outlook on near-term performance.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

ItemMar 2025Mar 2025Mar 2026Mar 2026
Equity Capital16161616
Reserves2,2752,2652,4152,469
Borrowings2002115
Total Liabilities2,6882,7142,8862,919
Fixed Assets800852838996
Investments1,0661,0281,0071,048
Total Assets2,6882,7142,8862,919

The balance sheet shows a stable capital structure with negligible debt (Borrowings ₹15 crore as of March 2026) and growing reserves, indicating prudent financial management. Total assets have increased steadily from ₹2,714 crore in March 2025 to ₹2,919 crore in March 2026, reflecting asset base expansion without leverage. The lack of debt and consistent equity base suggest management is not pursuing aggressive reinvestment or acquisitions, but rather maintaining a conservative capital allocation approach focused on preserving financial flexibility.

💰 Cash Flow Statement (₹ Cr)

ItemMar 2025
Operating+318
Investing-200
Financing-92
Net Cash Flow+26

👥 Shareholding Pattern

CategoryQ2FY26Q3FY26Q4FY26Q1FY27
Promoters69.7%69.7%69.7%69.7%
FII2.4%2.3%2.4%1.4%
DII6.8%6.3%6.3%6.3%
Public16.4%17.0%16.8%17.6%
# Shareholders54,15753,78852,73055,045

Institutional investor interest in FDC has shown a slight upward trend, with FII holdings rising from 2.32% in Q3FY26 to 2.43% in Q2FY26 before stabilizing, while DII holdings remained relatively steady around 6.3%. Promoter holding remains unchanged at 69.66% over the last five quarters, indicating no dilution or stake reduction. The growing number of public shareholders (55,045 as of Q1FY27) suggests increasing retail participation, but the low institutional ownership may reflect limited analyst coverage or sector-specific skepticism.

⚡ StockFin Pro Go Pro — bigger Radar, no daily limits Upgrade

⚖️ Peer Comparison — Pharmaceuticals

Company MCap (₹ Cr) P/E ROCE ROE D/E
SUNPHARMA 4.64 L Cr 38.4 18.7% 14.6% 0.05
DIVISLAB 2.45 L Cr 83.8 23.0% 17.4% 0.00
TORNTPHARM 1.90 L Cr 79.8 15.1% 25.7% 1.76
ZYDUSLIFE 1.15 L Cr 25.7 16.8% 16.6% 0.43
CIPLA 1.14 L Cr 33.9 13.2% 9.8% 0.01
LAURUSLABS 1.01 L Cr 92.0 20.8% 20.6% 0.45
LUPIN 98,424 17.4 27.9% 24.7% 0.26
MANKIND 98,293 48.1 13.9% 12.7% 0.38
DRREDDY 96,906 30.0 10.1% 8.4% 0.17
AUROPHARMA 95,300 25.9 12.8% 9.8% 0.20

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. The company's profitability appears highly sensitive to quarterly fluctuations, with operating profit declining from ₹128 crore in Q1FY27 to ₹92 crore in Q4FY26, raising concerns about sustainability. 2. Despite strong recent margins, the business remains concentrated in regulated consumer healthcare products, exposing it to regulatory scrutiny — as evidenced by the FSSAI labeling issue, even though currently mitigated by court intervention. 3. Low institutional ownership and stagnant promoter stake may limit investor confidence or liquidity, particularly amid broader sector headwinds.

📋 Recent Filings

🧠 Analyst's Read

FDC demonstrates solid profitability and financial discipline, but growth appears to have plateaued, and management provides no clear roadmap for future expansion. Investors should monitor upcoming quarterly results for signs of margin sustainability and watch for any strategic shifts in product portfolio or market positioning, particularly in light of ongoing regulatory oversight in key categories.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

✨ Deep Dive with AI on FDC

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-03.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when FDC files new disclosures

Track FDC filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track FDC — Free

Free account · 2 AI queries/day

⚡ StockFin Pro Go Pro — bigger Radar, no daily limits Upgrade

© 2026 StockFin.ai — AI-powered Indian stock research

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd